NEW YORK (GenomeWeb News) – Foundation Medicine today said that it will partner with Johnson & Johnson Pharmaceutical Research and Development in a biomarker identification collaboration.
Under the agreement, the partners will use Foundation Medicine's clinical cancer genomic test to identify biomarkers that will support J&JPRD's clinical development programs.
The Cambridge, Mass.-based company's cancer diagnostic test uses next-generation sequencing to analyze specimens for variations in over 200 cancer-related genes, and it is optimized for analysis of tissue complexities that are inherent in tumor genomes.
"Our test may help identify patients that are more likely to respond to targeted therapies, which could accelerate clinical development and give physicians additional ways to effectively treat patients," Foundation Medicine President and CEO Michael Pellini explained in a statement.
Financial terms of the agreement were not released.